Claims

1. A compound of the formula



where R_1 and R_2 are each H,
or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition:
a compound according to claim **1** formulated with a pharmaceutically acceptable carrier.

3. The pharmaceutical composition according to claim **2**, wherein the pharmaceutical acceptable carrier comprises one or more agents selected from the group consisting of lipids, interbilayer crosslinked multilamellar vesicles, biodegradeable poly(D,L-lactic-co-glycolic acid) [PLGA]-based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.

4. A composition comprising:
a compound according to claim **1** and one or more antigens selected for purposes of inducing an immune response against the antigen(s) when the composition is administered to an individual.

5. A method of inducing stimulator of interferon genes protein (STING)-dependent type I interferon production in an individual in need thereof, comprising:
administering a compound according to claim **1** to the individual in an amount sufficient to induce STING-dependent type I interferon production.

6. The method according to claim **5**, wherein the administration is directly into a tumor mass.